Title:
HER-2に結合するアンタゴニスト
Document Type and Number:
Japanese Patent JP2004501605
Kind Code:
A
Abstract:
There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO. 1 or SEQ ID NO:12, wherein the polypeptide binds to the extracellular domain ECD of HER-2 at an affinity of at least 108, (b) an isolated and glycosylated polypeptide having from about 300 to 419 amino acids taken from the sequence of SEQ ID NO:2 or SEQ ID NO:13, wherein the C terminal 79 amino acids are present, and wherein at least three N-linked glycosylation sites are present, (c) a monoclonal antibody that binds to the ECD of HER-2, and (d) combinations thereof, with the proviso that the agent cannot be the monoclonal antibody alone, and pharmaceutically acceptable carrier. Also disclosed are prognostic and diagnostic assays.
Inventors:
Clinton Gale
Henner William Dee
Evans adam
Henner William Dee
Evans adam
Application Number:
JP2001560693A
Publication Date:
January 22, 2004
Filing Date:
February 16, 2001
Export Citation:
Assignee:
Oregon Health Sciences University
International Classes:
G01N33/53; A61K38/00; A61K39/395; A61P1/00; A61P11/00; A61P15/00; A61P35/00; C07K14/47; C07K16/18; C07K16/32; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/09; C12Q1/68; G01N33/566; (IPC1-7): C12N15/09; A61K38/00; A61K39/395; A61P1/00; A61P11/00; A61P15/00; A61P35/00; C07K14/47; C07K16/18; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12Q1/68; G01N33/53; G01N33/566
Attorney, Agent or Firm:
Minoru Nakamura
Fumiaki Otsuka
Sadao Kumakura
Shishido Kaichi
Hideto Takeuchi
Toshio Imajo
Nobuo Ogawa
Village shrine Atsuo
Takaki Nishijima
Atsushi Hakoda
Fumiaki Otsuka
Sadao Kumakura
Shishido Kaichi
Hideto Takeuchi
Toshio Imajo
Nobuo Ogawa
Village shrine Atsuo
Takaki Nishijima
Atsushi Hakoda